ZUP1 promotes DNA repair and immune evasion to drive olaparib resistance in triple-negative breast cancer
ZUP1 facilitates olaparib resistance in TNBC by stabilizing PARP1 and enhancing DNA damage repair. Pharmacological inhibition of ZUP1 with procyanidin C1 represents a promising therapeutic strategy to overcome olaparib resistance in TNBC.
Authors
- Ying-Qing Li (ORCID: https://orcid.org/0000-0001-8187-6714)
- Xinhua Xie (ORCID: https://orcid.org/0000-0002-2775-0990)
- Shanshan Huang (ORCID: https://orcid.org/0000-0001-6706-5894)
- Yu Qiu (ORCID: https://orcid.org/0000-0001-8463-1958)
- Zelai He (ORCID: https://orcid.org/0000-0002-8547-6918)
- Yi Xie (ORCID: https://orcid.org/0000-0002-5476-1679)
- Linyu Wu (ORCID: https://orcid.org/0000-0002-2021-8336)
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Journal of Advanced Research
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1016/j.jare.2025.11.038
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00